Adam Bell

Company: Neuraly

Job title: Vice President, Translational Medicine and Regulatory Affairs

Seminars:

Advancing the Use of GLP-1s in Neurodegenerative Disease 12:30 pm - 1:00 pm

Exploring the neuroprotective effects of GLP-1s to reduce neuroinflammation, and increase synaptic plasticity Using the GLP-1s mechanisms in the hippocampus and cerebral cortex to promote neuronal growth and survival Uncovering the challenges surrounding tolerability and long-term safety in GLP-1s for neurological indicationsRead more

day: Day Two

DD01 – GLP-1/Glucagon Dual Agonist for the Treatment of MASH 2:30 pm - 3:00 pm

Developing a once weekly dual agonist of GLP-1 and glucagon receptors Exploring the benefits of half-life extension in obese/overweight patients with type 2 diabetes and MAFLD Assessing the benefits of DD01 in its ability to augment incretin therapy, acting through the glucagon receptor and enhancing liver lipolysis to treat the liver first Read more

day: Day One

Roundtable Discussion: Subcutaneous Vs Oral Administration in GLP-1: Will Oral Administration Really Improve Patient Adherence? 4:00 pm - 4:30 pm

Examining the benefits and challenges of oral GLP-1 delivery, considering gastrointestinal degradation, first pass metabolism and formulation challenges Comparing the efficacy and safety profiles of glycaemic control in oral and subcutaneous GLP-1s Exploring real world evidence and data on patient adherence to injectables and oral medication – will the oral delivery make the side effects…Read more

day: Day One